PolynovoCALZF 74 Pretax Margin % is 2.79% as of Dec. 2025. GuruFocus rates CALZF with a GF Score™ of 74/100 and a GF Value™ of $2.21 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Polynovo ranks better than 50.31% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Polynovo's Pre-Tax Income for the
six
months ended in Dec. 2025 was $1.30 Mil. Polynovo's Revenue for the
six
months ended in Dec. 2025 was $46.65 Mil. Therefore, Polynovo's pretax margin for the quarter that ended in Dec. 2025 was 2.79%.
The historical rank and industry rank for Polynovo's Pretax Margin % or its related term are showing as below:
CALZF'
s Pretax Margin % Range Over the Past 10 Years
Min: -138.36 Med: -17.12 Max: 5.91
Current: 2.74
CALZF's Pretax Margin % is ranked better than 50.31% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs CALZF: 2.74
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Polynovo Pretax Margin % Related Terms
Polynovo Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Polynovo's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CALZF vs ABT, SYK, MDT: Pretax Margin % Comparison
For the Medical Devices subindustry, Polynovo's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Polynovo's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polynovo (CALZF) has a Pretax Margin % of 2.79% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Polynovo and its competitors. According to the industry distribution chart, Polynovo ranks #406 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 49.7%.
Is Polynovo's Pretax Margin % too high?
Polynovo's current Pretax Margin % is 2.79%. The Medical Devices & Instruments industry median Pretax Margin % is 2.40. Polynovo's value of 2.79% is 16.3% above this industry median. Based on the distribution chart, Polynovo ranks #406 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Polynovo has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's Pretax Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #406 out of 817 companies for Pretax Margin %. This puts Polynovo in the upper half of its industry. The industry median Pretax Margin % is 2.40. Polynovo's value of 2.79% is 16.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.40, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polynovo's current Pretax Margin % of 2.79% is 16.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Polynovo and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current Pretax Margin % is 2.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.21, compared to a current price of $0.62 — trading 71.9% below its estimated fair value. The current Pretax Margin % is 2.79% and 16.3% above the Medical Devices & Instruments industry median of 2.40. Polynovo's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Polynovo (CALZF), the current Pretax Margin % is 2.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (CALZF) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of $0.62 is trading 71.9% below its estimated GF Value™ of $2.21.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for CALZF:
Pretax Margin %: 2.79%
GF Value™: $2.21 vs. price of $0.62 (71.9% below fair value)
Industry Position: 16.3% above the Medical Devices & Instruments median (#406 of 817)
No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
74GF Score
Get the complete analysis for CALZF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CALZF has been successfully added to your 
